Johnson & Johnson vs Kimberly-Clark
Side-by-side comparison of AI visibility scores, market position, and capabilities
FY2024 Sales: $88.8B (+4.3%) | Net Profit: $14.1B (+5.6%) | EPS: $5.79 | Adjusted EPS: $9.98 | FY2025 Guidance: Operational Sales Growth 2.5-3.5%, Adj EPS $10.75-$10.95 (+8.7% midpoint)
About
Johnson & Johnson is one of the world's largest healthcare companies, founded in 1886 by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson in New Brunswick, New Jersey, where the company remains headquartered. Established to manufacture ready-to-use surgical dressings at a time when post-operative infection was a leading cause of surgical mortality, J&J was built on the scientific principles of antiseptic surgery advocated by Joseph Lister. The company trades on the NYSE under ticker JNJ and has evolved over 135+ years from a consumer health products manufacturer into a focused MedTech and pharmaceutical enterprise, completing the spinoff of its consumer health segment (Kenvue) in 2023.\n\nJohnson & Johnson now operates through two segments: Innovative Medicine and MedTech. Innovative Medicine encompasses oncology, immunology, neuroscience, infectious disease, and cardiovascular pharmaceutical products — including blockbusters Darzalex, Stelara, Tremfya, and Rybrevant. The MedTech segment includes surgical robotics (Ottava platform in development), electrophysiology (Abiomed, Biosense Webster), orthopedics (DePuy Synthes), and surgery systems, serving hospitals and surgical centers worldwide. Following the Kenvue separation, J&J is a pure-play healthcare technology and pharmaceutical company with significantly higher growth and margin profiles than its historical blended consumer-pharma-medtech structure.\n\nJohnson & Johnson reported FY2024 sales of $88.8 billion, up 4.3% year over year, with net profit of $14.1 billion, up 5.6%. The company's Innovative Medicine segment continues to grow driven by oncology and immunology portfolio strength, while MedTech benefits from procedure volume recovery and robotic surgery adoption. J&J's scale, R&D pipeline depth, and global commercial infrastructure — spanning more than 60 countries — position it as one of the two or three most consequential healthcare enterprises globally, with a patent portfolio, clinical trial network, and regulatory expertise that are nearly impossible to replicate.
NYSE-listed (KMB) personal care company with Huggies, Kleenex, Scott, and Cottonelle at $20.1B revenue; competing directly with P&G Pampers and Charmin for global diaper and tissue market leadership.
About
Kimberly-Clark is a Dallas-based global consumer goods company manufacturing personal care, tissue, and health products under the Huggies (diapers), Kleenex (facial tissues), Scott (paper towels/toilet paper), Cottonelle (bathroom tissue), Pull-Ups (training pants), U by Kotex (feminine care), and Depend (adult incontinence) brand portfolio. Listed on NYSE (NYSE: KMB), Kimberly-Clark was founded in 1872 and generated $20.1 billion in net sales in fiscal year 2024, competing directly with Procter & Gamble (NYSE: PG, Pampers, Bounty, Charmin) in the diaper, tissue, and personal care categories globally.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Johnson & Johnson vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.